Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group

Saved in:

Bibliographic Details
Published in	Leukemia Vol. 37; no. 8; pp. 1723 - 1726
Main Authors	Lew-Derivry, Lucille, Marceau-Renaut, Alice, Fenwarth, Laurène, Cuccuini, Wendy, Ballerini, Paola, Ferreboeuf, Maxime, Guilmatre, Audrey, Petit, Arnaud, Gandemer, Virginie, Rialland, Fanny, Schneider, Pascale, Michel, Gérard, Bertrand, Yves, Baruchel, Andre, Preudhomme, Claude, Leverger, Guy, Lapillonne, Hélène
Format	Journal Article
Language	English
Published	London Nature Publishing Group UK 01.08.2023 Nature Publishing Group Springer Nature
Subjects	38/23 38/47 38/77 45 631/67/2324 692/699/67/69 692/700/1720 Acute myeloid leukemia Blood diseases Cancer Cancer Research Critical Care Medicine Cytogenetics Hematology Intensive Internal Medicine Kinases Letter Leukemia Life Sciences Medical prognosis Medicine Medicine & Public Health Mutation Nervous system Oncology Patients Pediatrics Remission (Medicine) Runx1 protein Toxicity Transcription factors Transplants & implants risk assessment cytology Humans major clinical study Article transcription factor RUNX1 Leukemia, Myeloid, Acute cytogenetics missense mutation gene deletion genetics leukemia remission acute myeloid leukemia event free survival Core Binding Factor Alpha 2 Subunit overall survival female France Child frameshift mutation human nonsense mutation gene mutation risk factor prognosis cancer prognosis gene frequency mutation pediatric patient controlled study cancer mortality RUNX1 protein, human adolescent RUNX1 gene male
Online Access	Get full text
ISSN	0887-6924 1476-5551 1476-5551
DOI	10.1038/s41375-023-01931-y

Cover

More Information
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Correspondence-2 content type line 23
ISSN:	0887-6924 1476-5551 1476-5551
DOI:	10.1038/s41375-023-01931-y